Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP651007.RAf2Xm9jUMlFBG_lyj9dsVoyc5wVUPZM4n0e2Elpo_7fs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP651007.RAf2Xm9jUMlFBG_lyj9dsVoyc5wVUPZM4n0e2Elpo_7fs130_assertion type Assertion NP651007.RAf2Xm9jUMlFBG_lyj9dsVoyc5wVUPZM4n0e2Elpo_7fs130_head.
- NP651007.RAf2Xm9jUMlFBG_lyj9dsVoyc5wVUPZM4n0e2Elpo_7fs130_assertion description "[Here, we administered gefitinib to two adenocarcinoma patients with liver cirrhosis, and one patient with EGFR gene mutation in exon 21 achieved long stable disease (SD) without any toxicity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP651007.RAf2Xm9jUMlFBG_lyj9dsVoyc5wVUPZM4n0e2Elpo_7fs130_provenance.
- NP651007.RAf2Xm9jUMlFBG_lyj9dsVoyc5wVUPZM4n0e2Elpo_7fs130_assertion evidence source_evidence_literature NP651007.RAf2Xm9jUMlFBG_lyj9dsVoyc5wVUPZM4n0e2Elpo_7fs130_provenance.
- NP651007.RAf2Xm9jUMlFBG_lyj9dsVoyc5wVUPZM4n0e2Elpo_7fs130_assertion SIO_000772 19755773 NP651007.RAf2Xm9jUMlFBG_lyj9dsVoyc5wVUPZM4n0e2Elpo_7fs130_provenance.
- NP651007.RAf2Xm9jUMlFBG_lyj9dsVoyc5wVUPZM4n0e2Elpo_7fs130_assertion wasDerivedFrom befree-20140225 NP651007.RAf2Xm9jUMlFBG_lyj9dsVoyc5wVUPZM4n0e2Elpo_7fs130_provenance.
- NP651007.RAf2Xm9jUMlFBG_lyj9dsVoyc5wVUPZM4n0e2Elpo_7fs130_assertion wasGeneratedBy ECO_0000203 NP651007.RAf2Xm9jUMlFBG_lyj9dsVoyc5wVUPZM4n0e2Elpo_7fs130_provenance.